Utility of 5-ALA for fluorescence-guided resection of brain metastases: a systematic review

Purpose 5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas. However, literature regarding 5-ALA-guided resection for brain metastases is limited. We conducted a systematic review to evaluate the ef...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuro-oncology Vol. 160; no. 3; pp. 669 - 675
Main Authors Shah, Harshal A., Leskinen, Sandra, Khilji, Hamza, Narayan, Vinayak, Ben-Shalom, Netanel, D’Amico, Randy S.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.12.2022
Springer Nature B.V
Subjects
Aminolevulinic Acid
Brain cancer
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - pathology
Brain Neoplasms - surgery
Brain tumors
Fluorescence
Glioma
Glioma - pathology
Humans
Medicine
Medicine & Public Health
Metastases
Metastasis
Neuroimaging
Neurology
Neuronavigation - methods
Oncology
Retrospective Studies
Review
Surgery, Computer-Assisted - methods
Survival
Systematic review
Tumors
Brain tumor
Fluorescence guided surgery
Brain metastases
Aminolevulinic acid
Protoporphyrin ix
Metastatic cancer
Online AccessGet full text
ISSN0167-594X
1573-7373
1573-7373
DOI10.1007/s11060-022-04188-0

Cover

Abstract Purpose 5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas. However, literature regarding 5-ALA-guided resection for brain metastases is limited. We conducted a systematic review to evaluate the efficacy of 5-ALA fluorescence for resection of metastatic brain tumors. Methods PubMed was queried for studies involving 5-ALA and brain metastases, and results were screened following PRISMA guidelines. Articles related to 5-ALA and brain metastasis were further assessed based on inclusion and exclusion criteria and results were analyzed for 5-ALA fluorescence rates stratified by tumor primary sites and histological subtypes. Results Of 421 identified search results, 10 studies were included and a total of 631 patients analyzed. Of these studies, 60% were retrospective in design. The reported rates of 5-ALA fluorescence in included brain metastases ranged from 27.6 to 86.9%, with variability across and within tumor types. No studies concluded improved operative outcomes or survival outcomes related to 5-ALA use. Conclusions Current studies regarding 5-ALA fluorescence in brain metastases are limited and do not confirm efficacy for improving extent of resection or post-operative survival. Fluorescence is variable across and within tumor types. Further studies are necessary to evaluate whether specific tumors may benefit from 5-ALA FGS or if changes in delivery protocols or fluorescence quantification may affect intraoperative utility.
AbstractList Purpose5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas. However, literature regarding 5-ALA-guided resection for brain metastases is limited. We conducted a systematic review to evaluate the efficacy of 5-ALA fluorescence for resection of metastatic brain tumors.MethodsPubMed was queried for studies involving 5-ALA and brain metastases, and results were screened following PRISMA guidelines. Articles related to 5-ALA and brain metastasis were further assessed based on inclusion and exclusion criteria and results were analyzed for 5-ALA fluorescence rates stratified by tumor primary sites and histological subtypes.ResultsOf 421 identified search results, 10 studies were included and a total of 631 patients analyzed. Of these studies, 60% were retrospective in design. The reported rates of 5-ALA fluorescence in included brain metastases ranged from 27.6 to 86.9%, with variability across and within tumor types. No studies concluded improved operative outcomes or survival outcomes related to 5-ALA use.ConclusionsCurrent studies regarding 5-ALA fluorescence in brain metastases are limited and do not confirm efficacy for improving extent of resection or post-operative survival. Fluorescence is variable across and within tumor types. Further studies are necessary to evaluate whether specific tumors may benefit from 5-ALA FGS or if changes in delivery protocols or fluorescence quantification may affect intraoperative utility.
Purpose 5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas. However, literature regarding 5-ALA-guided resection for brain metastases is limited. We conducted a systematic review to evaluate the efficacy of 5-ALA fluorescence for resection of metastatic brain tumors. Methods PubMed was queried for studies involving 5-ALA and brain metastases, and results were screened following PRISMA guidelines. Articles related to 5-ALA and brain metastasis were further assessed based on inclusion and exclusion criteria and results were analyzed for 5-ALA fluorescence rates stratified by tumor primary sites and histological subtypes. Results Of 421 identified search results, 10 studies were included and a total of 631 patients analyzed. Of these studies, 60% were retrospective in design. The reported rates of 5-ALA fluorescence in included brain metastases ranged from 27.6 to 86.9%, with variability across and within tumor types. No studies concluded improved operative outcomes or survival outcomes related to 5-ALA use. Conclusions Current studies regarding 5-ALA fluorescence in brain metastases are limited and do not confirm efficacy for improving extent of resection or post-operative survival. Fluorescence is variable across and within tumor types. Further studies are necessary to evaluate whether specific tumors may benefit from 5-ALA FGS or if changes in delivery protocols or fluorescence quantification may affect intraoperative utility.
5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas. However, literature regarding 5-ALA-guided resection for brain metastases is limited. We conducted a systematic review to evaluate the efficacy of 5-ALA fluorescence for resection of metastatic brain tumors. PubMed was queried for studies involving 5-ALA and brain metastases, and results were screened following PRISMA guidelines. Articles related to 5-ALA and brain metastasis were further assessed based on inclusion and exclusion criteria and results were analyzed for 5-ALA fluorescence rates stratified by tumor primary sites and histological subtypes. Of 421 identified search results, 10 studies were included and a total of 631 patients analyzed. Of these studies, 60% were retrospective in design. The reported rates of 5-ALA fluorescence in included brain metastases ranged from 27.6 to 86.9%, with variability across and within tumor types. No studies concluded improved operative outcomes or survival outcomes related to 5-ALA use. Current studies regarding 5-ALA fluorescence in brain metastases are limited and do not confirm efficacy for improving extent of resection or post-operative survival. Fluorescence is variable across and within tumor types. Further studies are necessary to evaluate whether specific tumors may benefit from 5-ALA FGS or if changes in delivery protocols or fluorescence quantification may affect intraoperative utility.
5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas. However, literature regarding 5-ALA-guided resection for brain metastases is limited. We conducted a systematic review to evaluate the efficacy of 5-ALA fluorescence for resection of metastatic brain tumors.PURPOSE5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas. However, literature regarding 5-ALA-guided resection for brain metastases is limited. We conducted a systematic review to evaluate the efficacy of 5-ALA fluorescence for resection of metastatic brain tumors.PubMed was queried for studies involving 5-ALA and brain metastases, and results were screened following PRISMA guidelines. Articles related to 5-ALA and brain metastasis were further assessed based on inclusion and exclusion criteria and results were analyzed for 5-ALA fluorescence rates stratified by tumor primary sites and histological subtypes.METHODSPubMed was queried for studies involving 5-ALA and brain metastases, and results were screened following PRISMA guidelines. Articles related to 5-ALA and brain metastasis were further assessed based on inclusion and exclusion criteria and results were analyzed for 5-ALA fluorescence rates stratified by tumor primary sites and histological subtypes.Of 421 identified search results, 10 studies were included and a total of 631 patients analyzed. Of these studies, 60% were retrospective in design. The reported rates of 5-ALA fluorescence in included brain metastases ranged from 27.6 to 86.9%, with variability across and within tumor types. No studies concluded improved operative outcomes or survival outcomes related to 5-ALA use.RESULTSOf 421 identified search results, 10 studies were included and a total of 631 patients analyzed. Of these studies, 60% were retrospective in design. The reported rates of 5-ALA fluorescence in included brain metastases ranged from 27.6 to 86.9%, with variability across and within tumor types. No studies concluded improved operative outcomes or survival outcomes related to 5-ALA use.Current studies regarding 5-ALA fluorescence in brain metastases are limited and do not confirm efficacy for improving extent of resection or post-operative survival. Fluorescence is variable across and within tumor types. Further studies are necessary to evaluate whether specific tumors may benefit from 5-ALA FGS or if changes in delivery protocols or fluorescence quantification may affect intraoperative utility.CONCLUSIONSCurrent studies regarding 5-ALA fluorescence in brain metastases are limited and do not confirm efficacy for improving extent of resection or post-operative survival. Fluorescence is variable across and within tumor types. Further studies are necessary to evaluate whether specific tumors may benefit from 5-ALA FGS or if changes in delivery protocols or fluorescence quantification may affect intraoperative utility.
Author Narayan, Vinayak
Leskinen, Sandra
Khilji, Hamza
Ben-Shalom, Netanel
Shah, Harshal A.
D’Amico, Randy S.
Author_xml – sequence: 1
  givenname: Harshal A.
  orcidid: 0000-0003-4088-6232
  surname: Shah
  fullname: Shah, Harshal A.
  email: hshah5@northwell.edu
  organization: Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
– sequence: 2
  givenname: Sandra
  surname: Leskinen
  fullname: Leskinen, Sandra
  organization: State University of New York Downstate Medical Center
– sequence: 3
  givenname: Hamza
  surname: Khilji
  fullname: Khilji, Hamza
  organization: State University of New York Downstate Medical Center
– sequence: 4
  givenname: Vinayak
  surname: Narayan
  fullname: Narayan, Vinayak
  organization: Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
– sequence: 5
  givenname: Netanel
  surname: Ben-Shalom
  fullname: Ben-Shalom, Netanel
  organization: Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
– sequence: 6
  givenname: Randy S.
  surname: D’Amico
  fullname: D’Amico, Randy S.
  organization: Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36370294$$D View this record in MEDLINE/PubMed
BookMark eNp9kVFrFDEUhYNU7Lb6B3yQAV98id7kTiZZ35aiVVjwxYLgQ8hm7pSUmUlNMpX992a7VaEPhUAIfOfek3PO2MkcZ2LstYD3AkB_yEJABxyk5NAKYzg8YyuhNHKNGk_YCkSnuVq3P07ZWc43ANBqFC_YKXaoQa7bFft5VcIYyr6JQ6P4ZrtphpiaYVxiouxp9sSvl9BT39Q3-RLifEB3yYW5mai4XA_lj41r8j4XmlwJvrJ3gX6_ZM8HN2Z69XCfs6vPn75ffOHbb5dfLzZb7lGrwsmAAOfXSnpt-tah8Sjrz_reoHJOtQC4HozAvneAg-g6LUgNO6UV-k4jnrN3x7m3Kf5aKBc7hep9HN1McclWalSmU53sKvr2EXoTlzRXd5VSCkBIKSv15oFadhP19jaFyaW9_RtbBeQR8CnmnGj4hwiwh27ssRtbu7H33VioIvNI5ENxh0RLTXN8WopHaa575mtK_20_ofoDfi6gow
CitedBy_id crossref_primary_10_1007_s11060_024_04698_z
crossref_primary_10_1227_ons_0000000000001397
crossref_primary_10_14791_btrt_2023_0014
crossref_primary_10_1016_j_wneu_2023_07_030
crossref_primary_10_3390_ijms24054554
crossref_primary_10_3390_jcm13206198
crossref_primary_10_1097_JS9_0000000000001847
crossref_primary_10_1227_neuprac_0000000000000121
Cites_doi 10.1038/bjc.2011.12
10.1200/JCO.21.02314
10.3171/2008.8.JNS08448
10.12688/f1000research.15903.1
10.14791/btrt.2019.7.e38
10.1093/neuonc/not112
10.1007/s11912-011-0203-y
10.1038/s41571-020-00447-z
10.1227/01.neu.0000303209.38360.e6
10.1001/jama.280.17.1485
10.1089/pho.2012.3469
10.1016/j.ijrobp.2006.03.050
10.1016/S1011-1344(98)00176-6
10.1016/j.pdpdt.2022.102864
10.1007/s00701-011-1200-5
10.3389/fonc.2019.00620
10.1002/cncr.30088
10.1016/j.wneu.2021.02.118
10.1007/978-3-319-21359-0_3
10.4103/2152-7806.111296
10.1136/bmjopen-2021-056059
10.1016/j.wnsx.2019.100069
10.1016/j.pdpdt.2011.12.004
10.1007/s10143-016-0745-4
10.1007/s10585-019-09986-x
10.1016/j.pdpdt.2019.01.009
10.1371/journal.pone.0063682
10.3390/cancers14030617
10.1016/S1470-2045(06)70665-9
10.1016/j.pdpdt.2013.02.001
10.1007/s00701-012-1369-2
10.3171/2021.12.JNS211724
10.18632/oncotarget.4201
10.1007/s11060-004-9603-2
10.1007/s10014-007-0223-3
10.1007/s10143-018-1013-6
10.1007/s00701-019-04007-y
10.1007/s00701-021-05104-7
10.18632/oncotarget.27688
10.3171/2019.6.JNS1997
10.1007/s10143-015-0695-2
10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s11060-022-04188-0
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1573-7373
EndPage 675
ExternalDocumentID 36370294
10_1007_s11060_022_04188_0
Genre Systematic Review
Journal Article
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
1SB
2.D
203
28-
29L
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
67Z
6NX
78A
7X7
88E
8AO
8C1
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFJLC
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Y
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAK
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
RNS
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
ZXP
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7TK
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c375t-e8010ac952c78d4a38c32106dd835aa540039f813dda03f16671e5fb5753c6733
IEDL.DBID 8C1
ISSN 0167-594X
1573-7373
IngestDate Fri Sep 05 08:25:21 EDT 2025
Sat Aug 16 17:21:21 EDT 2025
Mon Jul 21 05:46:40 EDT 2025
Tue Jul 01 02:14:16 EDT 2025
Thu Apr 24 23:07:48 EDT 2025
Fri Feb 21 02:43:47 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Brain tumor
Fluorescence guided surgery
Brain metastases
Aminolevulinic acid
Protoporphyrin ix
Metastatic cancer
Language English
License 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-e8010ac952c78d4a38c32106dd835aa540039f813dda03f16671e5fb5753c6733
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Undefined-1
ObjectType-Review-4
content type line 23
ORCID 0000-0003-4088-6232
PMID 36370294
PQID 2755001222
PQPubID 37423
PageCount 7
ParticipantIDs proquest_miscellaneous_2735865626
proquest_journals_2755001222
pubmed_primary_36370294
crossref_primary_10_1007_s11060_022_04188_0
crossref_citationtrail_10_1007_s11060_022_04188_0
springer_journals_10_1007_s11060_022_04188_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20221200
2022-12-00
2022-Dec
20221201
PublicationDateYYYYMMDD 2022-12-01
PublicationDate_xml – month: 12
  year: 2022
  text: 20221200
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
PublicationTitle Journal of neuro-oncology
PublicationTitleAbbrev J Neurooncol
PublicationTitleAlternate J Neurooncol
PublicationYear 2022
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References Miyatake (CR34) 2007; 61
Kamp (CR35) 2018; 41
Suero Molina (CR46) 2022; 137
Stummer (CR38) 2019; 161
Siam (CR9) 2015; 6
Stummer (CR16) 1998; 45
Marhold (CR25) 2022; 39
Dadario (CR13) 2021; 150
Ferraro (CR22) 2016; 39
Zimm, Wampler, Stablein, Hazra, Young (CR26) 1981; 48
Stummer (CR14) 2006; 7
Gandhi (CR17) 2019; 9
Neves (CR28) 2001; 20
Stelzer (CR5) 2013; 4
Omoto (CR41) 2019; 25
Kotecha (CR6) 2018; 7
Widhalm (CR40) 2019; 133
Guyotat (CR24) 2016; 43
Utsuki (CR44) 2007; 24
Zhao (CR12) 2013; 8
Hagiya (CR43) 2013; 10
Ji, Kim, Park (CR37) 2019; 7
Masubuchi (CR33) 2013; 31
Lowery, Yu (CR4) 2017; 1867
Baig Mirza (CR18) 2021; 3
Kamp (CR47) 2012; 154
Marhold (CR36) 2020; 133
Patchell (CR1) 1998; 280
Teng (CR20) 2011; 104
Schatlo (CR32) 2019; 5
Nayak, Lee, Wen (CR2) 2012; 14
Hagiya (CR42) 2011; 9
Baumert (CR29) 2006; 66
CR45
Knipps (CR39) 2019; 36
Berghoff (CR10) 2013; 15
Hussein (CR30) 2020; 11
Duffner (CR15) 2005; 71
Mansouri (CR19) 2016; 122
Kamp (CR31) 2012; 154
Vogelbaum (CR7) 2021; 40
Ahrens (CR23) 2022; 14
Solomou (CR21) 2022; 12
Hatiboglu, Akdur, Sawaya (CR3) 2020; 43
Winther (CR8) 2022; 164
Weller (CR11) 2021; 18
Yoo (CR27) 2009; 110
F Duffner (4188_CR15) 2005; 71
F Marhold (4188_CR25) 2022; 39
MA Hatiboglu (4188_CR3) 2020; 43
A Mansouri (4188_CR19) 2016; 122
N Ferraro (4188_CR22) 2016; 39
S Utsuki (4188_CR44) 2007; 24
MA Vogelbaum (4188_CR7) 2021; 40
Y Hagiya (4188_CR43) 2013; 10
L Siam (4188_CR9) 2015; 6
S Neves (4188_CR28) 2001; 20
BG Baumert (4188_CR29) 2006; 66
A Baig Mirza (4188_CR18) 2021; 3
FJ Lowery (4188_CR4) 2017; 1867
F Marhold (4188_CR36) 2020; 133
KJ Stelzer (4188_CR5) 2013; 4
M Weller (4188_CR11) 2021; 18
S Miyatake (4188_CR34) 2007; 61
NB Dadario (4188_CR13) 2021; 150
G Widhalm (4188_CR40) 2019; 133
LC Ahrens (4188_CR23) 2022; 14
H Yoo (4188_CR27) 2009; 110
W Stummer (4188_CR38) 2019; 161
MA Kamp (4188_CR47) 2012; 154
RR Winther (4188_CR8) 2022; 164
S Zimm (4188_CR26) 1981; 48
S Zhao (4188_CR12) 2013; 8
R Kotecha (4188_CR6) 2018; 7
J Knipps (4188_CR39) 2019; 36
AS Berghoff (4188_CR10) 2013; 15
L Teng (4188_CR20) 2011; 104
A Hussein (4188_CR30) 2020; 11
B Schatlo (4188_CR32) 2019; 5
MA Kamp (4188_CR35) 2018; 41
T Masubuchi (4188_CR33) 2013; 31
G Solomou (4188_CR21) 2022; 12
W Stummer (4188_CR16) 1998; 45
SY Ji (4188_CR37) 2019; 7
J Guyotat (4188_CR24) 2016; 43
L Nayak (4188_CR2) 2012; 14
4188_CR45
W Stummer (4188_CR14) 2006; 7
S Gandhi (4188_CR17) 2019; 9
K Omoto (4188_CR41) 2019; 25
Y Hagiya (4188_CR42) 2011; 9
RA Patchell (4188_CR1) 1998; 280
E Suero Molina (4188_CR46) 2022; 137
MA Kamp (4188_CR31) 2012; 154
References_xml – volume: 104
  start-page: 798
  year: 2011
  end-page: 807
  ident: CR20
  article-title: Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.12
– ident: CR45
– volume: 40
  start-page: 492
  issue: 5
  year: 2021
  end-page: 516
  ident: CR7
  article-title: Treatment for brain metastases: ASCO-SNO-ASTRO guideline
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.02314
– volume: 110
  start-page: 730
  issue: 4
  year: 2009
  end-page: 736
  ident: CR27
  article-title: Reduced local recurrence of a single brain metastasis through microscopic total resection: clinical article
  publication-title: J Neurosurg JNS
  doi: 10.3171/2008.8.JNS08448
– volume: 3
  start-page: vdab047
  issue: 1
  year: 2021
  ident: CR18
  article-title: 5-Aminolevulinic acid-guided resection improves the overall survival of patients with glioblastoma-a comparative cohort study of 343 patients
  publication-title: Neurooncol Adv.
– volume: 7
  start-page: F1000
  year: 2018
  ident: CR6
  article-title: Recent advances in managing brain metastasis
  publication-title: F1000Res
  doi: 10.12688/f1000research.15903.1
– volume: 7
  start-page: 98
  issue: 2
  year: 2019
  end-page: 104
  ident: CR37
  article-title: Experience profiling of fluorescence-guided surgery II: non-glioma pathologies
  publication-title: Brain Tumor Res Treat
  doi: 10.14791/btrt.2019.7.e38
– volume: 15
  start-page: 1664
  issue: 12
  year: 2013
  end-page: 1672
  ident: CR10
  article-title: Invasion patterns in brain metastases of solid cancers
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/not112
– volume: 14
  start-page: 48
  issue: 1
  year: 2012
  end-page: 54
  ident: CR2
  article-title: Epidemiology of brain metastases
  publication-title: Curr Oncol Rep
  doi: 10.1007/s11912-011-0203-y
– volume: 18
  start-page: 170
  issue: 3
  year: 2021
  end-page: 186
  ident: CR11
  article-title: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-020-00447-z
– volume: 61
  start-page: E1101-3
  issue: 5
  year: 2007
  ident: CR34
  article-title: Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: case report
  publication-title: Neurosurgery
  doi: 10.1227/01.neu.0000303209.38360.e6
– volume: 280
  start-page: 1485
  issue: 17
  year: 1998
  end-page: 1489
  ident: CR1
  article-title: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial
  publication-title: JAMA
  doi: 10.1001/jama.280.17.1485
– volume: 31
  start-page: 428
  issue: 9
  year: 2013
  end-page: 433
  ident: CR33
  article-title: Experimental study to understand nonspecific protoporphyrin IX fluorescence in brain tissues near tumors after 5-aminolevulinic acid administration
  publication-title: Photomed Laser Surg
  doi: 10.1089/pho.2012.3469
– volume: 66
  start-page: 187
  issue: 1
  year: 2006
  end-page: 194
  ident: CR29
  article-title: A pathology-based substrate for target definition in radiosurgery of brain metastases
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2006.03.050
– volume: 45
  start-page: 160
  issue: 2–3
  year: 1998
  end-page: 169
  ident: CR16
  article-title: In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid
  publication-title: J Photochem Photobiol B
  doi: 10.1016/S1011-1344(98)00176-6
– volume: 39
  year: 2022
  ident: CR25
  article-title: Does pigmentation, hemosiderin and blood effect visible 5-ALA fluorescence in cerebral melanoma metastasis?
  publication-title: Photodiagn Photodyn Ther
  doi: 10.1016/j.pdpdt.2022.102864
– volume: 154
  start-page: 223
  issue: 2
  year: 2012
  end-page: 228
  ident: CR31
  article-title: 5-Aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study
  publication-title: Acta Neurochir
  doi: 10.1007/s00701-011-1200-5
– volume: 9
  start-page: 620
  year: 2019
  ident: CR17
  article-title: Survival outcomes among patients with high-grade glioma treated with 5-aminolevulinic acid-guided surgery: a systematic review and meta-analysis
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.00620
– volume: 122
  start-page: 2469
  issue: 16
  year: 2016
  end-page: 2478
  ident: CR19
  article-title: The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: a systematic review
  publication-title: Cancer
  doi: 10.1002/cncr.30088
– volume: 150
  start-page: 9
  year: 2021
  end-page: 16
  ident: CR13
  article-title: 5-aminolevulinic acid-shedding light on where to focus
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2021.02.118
– volume: 43
  start-page: 61
  year: 2016
  end-page: 90
  ident: CR24
  article-title: 5-aminolevulinic acid-protoporphyrin IX fluorescence-guided surgery of high-grade gliomas: a systematic review
  publication-title: Adv Tech Stand Neurosurg
  doi: 10.1007/978-3-319-21359-0_3
– volume: 4
  start-page: S192
  year: 2013
  ident: CR5
  article-title: Epidemiology and prognosis of brain metastases
  publication-title: Surg Neurol Int
  doi: 10.4103/2152-7806.111296
– volume: 12
  issue: 7
  year: 2022
  ident: CR21
  article-title: Utility of 5-ALA for resection of CNS tumours other than high-grade gliomas: a protocol for a systematic review
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2021-056059
– volume: 5
  start-page: 100069
  year: 2019
  ident: CR32
  article-title: 5-aminolevulinic acid fluorescence indicates perilesional brain infiltration in brain metastases
  publication-title: World Neurosurg X
  doi: 10.1016/j.wnsx.2019.100069
– volume: 9
  start-page: 204
  issue: 3
  year: 2011
  end-page: 214
  ident: CR42
  article-title: Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro
  publication-title: Photodiagn Photodyn Ther
  doi: 10.1016/j.pdpdt.2011.12.004
– volume: 41
  start-page: 3
  issue: 1
  year: 2018
  end-page: 18
  ident: CR35
  article-title: Various shades of red-a systematic analysis of qualitative estimation of ALA-derived fluorescence in neurosurgery
  publication-title: Neurosurg Rev
  doi: 10.1007/s10143-016-0745-4
– volume: 36
  start-page: 467
  issue: 5
  year: 2019
  end-page: 475
  ident: CR39
  article-title: Quantification of PpIX-fluorescence of cerebral metastases: a pilot study
  publication-title: Clin Exp Metas
  doi: 10.1007/s10585-019-09986-x
– volume: 25
  start-page: 309
  year: 2019
  end-page: 316
  ident: CR41
  article-title: Expression of peptide transporter 1 has a positive correlation in protoporphyrin IX accumulation induced by 5-aminolevulinic acid with photodynamic detection of non-small cell lung cancer and metastatic brain tumor specimens originating from non-small cell lung cancer
  publication-title: Photodiagn Photodyn Ther
  doi: 10.1016/j.pdpdt.2019.01.009
– volume: 1867
  start-page: 49
  issue: 1
  year: 2017
  end-page: 57
  ident: CR4
  article-title: Brain metastasis: unique challenges and open opportunities
  publication-title: Biochim Biophys Acta (BBA)
– volume: 8
  start-page: e63682
  issue: 5
  year: 2013
  ident: CR12
  article-title: Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0063682
– volume: 14
  start-page: 617
  issue: 3
  year: 2022
  ident: CR23
  article-title: Effect of 5-aminolevulinic acid and sodium fluorescein on the extent of resection in high-grade gliomas and brain metastasis
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14030617
– volume: 20
  start-page: 38
  issue: 1
  year: 2001
  end-page: 42
  ident: CR28
  article-title: Pseudogliomatous growth pattern of anaplastic small cell carcinomas metastatic to the brain
  publication-title: Clin Neuropathol
– volume: 7
  start-page: 392
  issue: 5
  year: 2006
  end-page: 401
  ident: CR14
  article-title: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(06)70665-9
– volume: 10
  start-page: 288
  issue: 3
  year: 2013
  end-page: 295
  ident: CR43
  article-title: Expression levels of PEPT1 and ABCG2 play key roles in 5-aminolevulinic acid (ALA)-induced tumor-specific protoporphyrin IX (PpIX) accumulation in bladder cancer
  publication-title: Photodiagn Photodyn Ther
  doi: 10.1016/j.pdpdt.2013.02.001
– volume: 154
  start-page: 1269
  issue: 7
  year: 2012
  end-page: 1273
  ident: CR47
  article-title: Is it a glioblastoma? In dubio pro 5-ALA!
  publication-title: Acta Neurochir
  doi: 10.1007/s00701-012-1369-2
– volume: 133
  start-page: 1
  year: 2019
  end-page: 10
  ident: CR40
  article-title: The value of visible 5-ALA fluorescence and quantitative protoporphyrin IX analysis for improved surgery of suspected low-grade gliomas
  publication-title: J Neurosurg
– volume: 137
  start-page: 943
  issue: 4
  year: 2022
  end-page: 952
  ident: CR46
  article-title: Double dose of 5-aminolevulinic acid and its effect on protoporphyrin IX accumulation in low-grade glioma
  publication-title: J Neurosurg
  doi: 10.3171/2021.12.JNS211724
– volume: 6
  start-page: 29254
  issue: 30
  year: 2015
  end-page: 29267
  ident: CR9
  article-title: The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4201
– volume: 71
  start-page: 107
  issue: 2
  year: 2005
  end-page: 111
  ident: CR15
  article-title: Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX
  publication-title: J Neurooncol
  doi: 10.1007/s11060-004-9603-2
– volume: 24
  start-page: 53
  year: 2007
  ident: CR44
  article-title: Fluorescence-guided resection of metastatic brain tumors using a 5-aminolevulinic acid-induced protoporphyrin IX: pathological study
  publication-title: Brain Tumor Pathol
  doi: 10.1007/s10014-007-0223-3
– volume: 43
  start-page: 483
  issue: 2
  year: 2020
  end-page: 495
  ident: CR3
  article-title: Neurosurgical management of patients with brain metastasis
  publication-title: Neurosurg Rev
  doi: 10.1007/s10143-018-1013-6
– volume: 161
  start-page: 2083
  issue: 10
  year: 2019
  end-page: 2098
  ident: CR38
  article-title: Intraoperative fluorescence diagnosis in the brain: a systematic review and suggestions for future standards on reporting diagnostic accuracy and clinical utility
  publication-title: Acta Neurochir (Wien)
  doi: 10.1007/s00701-019-04007-y
– volume: 164
  start-page: 2773
  issue: 10
  year: 2022
  end-page: 2780
  ident: CR8
  article-title: Surgery for brain metastases-impact of the extent of resection
  publication-title: Acta Neurochir
  doi: 10.1007/s00701-021-05104-7
– volume: 11
  start-page: 3026
  issue: 32
  year: 2020
  end-page: 3034
  ident: CR30
  article-title: Survival after resection of brain metastases with white light microscopy versus fluorescence-guidance: a matched cohort analysis of the Metastasys study data
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27688
– volume: 133
  start-page: 1032
  issue: 4
  year: 2020
  end-page: 1043
  ident: CR36
  article-title: Detailed analysis of 5-aminolevulinic acid induced fluorescence in different brain metastases at two specialized neurosurgical centers: experience in 157 cases
  publication-title: J Neurosurg
  doi: 10.3171/2019.6.JNS1997
– volume: 39
  start-page: 545
  issue: 4
  year: 2016
  end-page: 555
  ident: CR22
  article-title: The role of 5-aminolevulinic acid in brain tumor surgery: a systematic review
  publication-title: Neurosurg Rev
  doi: 10.1007/s10143-015-0695-2
– volume: 48
  start-page: 384
  issue: 2
  year: 1981
  end-page: 394
  ident: CR26
  article-title: Intracerebral metastases in solid-tumor patients: natural history and results of treatment
  publication-title: Cancer
  doi: 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8
– volume: 41
  start-page: 3
  issue: 1
  year: 2018
  ident: 4188_CR35
  publication-title: Neurosurg Rev
  doi: 10.1007/s10143-016-0745-4
– volume: 45
  start-page: 160
  issue: 2–3
  year: 1998
  ident: 4188_CR16
  publication-title: J Photochem Photobiol B
  doi: 10.1016/S1011-1344(98)00176-6
– volume: 133
  start-page: 1032
  issue: 4
  year: 2020
  ident: 4188_CR36
  publication-title: J Neurosurg
  doi: 10.3171/2019.6.JNS1997
– volume: 104
  start-page: 798
  year: 2011
  ident: 4188_CR20
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.12
– volume: 31
  start-page: 428
  issue: 9
  year: 2013
  ident: 4188_CR33
  publication-title: Photomed Laser Surg
  doi: 10.1089/pho.2012.3469
– volume: 61
  start-page: E1101-3
  issue: 5
  year: 2007
  ident: 4188_CR34
  publication-title: Neurosurgery
  doi: 10.1227/01.neu.0000303209.38360.e6
– volume: 36
  start-page: 467
  issue: 5
  year: 2019
  ident: 4188_CR39
  publication-title: Clin Exp Metas
  doi: 10.1007/s10585-019-09986-x
– volume: 7
  start-page: 98
  issue: 2
  year: 2019
  ident: 4188_CR37
  publication-title: Brain Tumor Res Treat
  doi: 10.14791/btrt.2019.7.e38
– volume: 164
  start-page: 2773
  issue: 10
  year: 2022
  ident: 4188_CR8
  publication-title: Acta Neurochir
  doi: 10.1007/s00701-021-05104-7
– volume: 9
  start-page: 620
  year: 2019
  ident: 4188_CR17
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.00620
– volume: 3
  start-page: vdab047
  issue: 1
  year: 2021
  ident: 4188_CR18
  publication-title: Neurooncol Adv.
– volume: 39
  start-page: 545
  issue: 4
  year: 2016
  ident: 4188_CR22
  publication-title: Neurosurg Rev
  doi: 10.1007/s10143-015-0695-2
– volume: 137
  start-page: 943
  issue: 4
  year: 2022
  ident: 4188_CR46
  publication-title: J Neurosurg
  doi: 10.3171/2021.12.JNS211724
– volume: 150
  start-page: 9
  year: 2021
  ident: 4188_CR13
  publication-title: World Neurosurg
  doi: 10.1016/j.wneu.2021.02.118
– volume: 110
  start-page: 730
  issue: 4
  year: 2009
  ident: 4188_CR27
  publication-title: J Neurosurg JNS
  doi: 10.3171/2008.8.JNS08448
– volume: 6
  start-page: 29254
  issue: 30
  year: 2015
  ident: 4188_CR9
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4201
– volume: 20
  start-page: 38
  issue: 1
  year: 2001
  ident: 4188_CR28
  publication-title: Clin Neuropathol
– volume: 154
  start-page: 1269
  issue: 7
  year: 2012
  ident: 4188_CR47
  publication-title: Acta Neurochir
  doi: 10.1007/s00701-012-1369-2
– volume: 9
  start-page: 204
  issue: 3
  year: 2011
  ident: 4188_CR42
  publication-title: Photodiagn Photodyn Ther
  doi: 10.1016/j.pdpdt.2011.12.004
– ident: 4188_CR45
– volume: 18
  start-page: 170
  issue: 3
  year: 2021
  ident: 4188_CR11
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-020-00447-z
– volume: 43
  start-page: 483
  issue: 2
  year: 2020
  ident: 4188_CR3
  publication-title: Neurosurg Rev
  doi: 10.1007/s10143-018-1013-6
– volume: 40
  start-page: 492
  issue: 5
  year: 2021
  ident: 4188_CR7
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.21.02314
– volume: 133
  start-page: 1
  year: 2019
  ident: 4188_CR40
  publication-title: J Neurosurg
– volume: 10
  start-page: 288
  issue: 3
  year: 2013
  ident: 4188_CR43
  publication-title: Photodiagn Photodyn Ther
  doi: 10.1016/j.pdpdt.2013.02.001
– volume: 1867
  start-page: 49
  issue: 1
  year: 2017
  ident: 4188_CR4
  publication-title: Biochim Biophys Acta (BBA)
– volume: 11
  start-page: 3026
  issue: 32
  year: 2020
  ident: 4188_CR30
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27688
– volume: 161
  start-page: 2083
  issue: 10
  year: 2019
  ident: 4188_CR38
  publication-title: Acta Neurochir (Wien)
  doi: 10.1007/s00701-019-04007-y
– volume: 7
  start-page: F1000
  year: 2018
  ident: 4188_CR6
  publication-title: F1000Res
  doi: 10.12688/f1000research.15903.1
– volume: 12
  issue: 7
  year: 2022
  ident: 4188_CR21
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2021-056059
– volume: 14
  start-page: 617
  issue: 3
  year: 2022
  ident: 4188_CR23
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14030617
– volume: 154
  start-page: 223
  issue: 2
  year: 2012
  ident: 4188_CR31
  publication-title: Acta Neurochir
  doi: 10.1007/s00701-011-1200-5
– volume: 24
  start-page: 53
  year: 2007
  ident: 4188_CR44
  publication-title: Brain Tumor Pathol
  doi: 10.1007/s10014-007-0223-3
– volume: 122
  start-page: 2469
  issue: 16
  year: 2016
  ident: 4188_CR19
  publication-title: Cancer
  doi: 10.1002/cncr.30088
– volume: 43
  start-page: 61
  year: 2016
  ident: 4188_CR24
  publication-title: Adv Tech Stand Neurosurg
  doi: 10.1007/978-3-319-21359-0_3
– volume: 280
  start-page: 1485
  issue: 17
  year: 1998
  ident: 4188_CR1
  publication-title: JAMA
  doi: 10.1001/jama.280.17.1485
– volume: 48
  start-page: 384
  issue: 2
  year: 1981
  ident: 4188_CR26
  publication-title: Cancer
  doi: 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8
– volume: 4
  start-page: S192
  year: 2013
  ident: 4188_CR5
  publication-title: Surg Neurol Int
  doi: 10.4103/2152-7806.111296
– volume: 8
  start-page: e63682
  issue: 5
  year: 2013
  ident: 4188_CR12
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0063682
– volume: 39
  year: 2022
  ident: 4188_CR25
  publication-title: Photodiagn Photodyn Ther
  doi: 10.1016/j.pdpdt.2022.102864
– volume: 25
  start-page: 309
  year: 2019
  ident: 4188_CR41
  publication-title: Photodiagn Photodyn Ther
  doi: 10.1016/j.pdpdt.2019.01.009
– volume: 7
  start-page: 392
  issue: 5
  year: 2006
  ident: 4188_CR14
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(06)70665-9
– volume: 14
  start-page: 48
  issue: 1
  year: 2012
  ident: 4188_CR2
  publication-title: Curr Oncol Rep
  doi: 10.1007/s11912-011-0203-y
– volume: 66
  start-page: 187
  issue: 1
  year: 2006
  ident: 4188_CR29
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2006.03.050
– volume: 71
  start-page: 107
  issue: 2
  year: 2005
  ident: 4188_CR15
  publication-title: J Neurooncol
  doi: 10.1007/s11060-004-9603-2
– volume: 5
  start-page: 100069
  year: 2019
  ident: 4188_CR32
  publication-title: World Neurosurg X
  doi: 10.1016/j.wnsx.2019.100069
– volume: 15
  start-page: 1664
  issue: 12
  year: 2013
  ident: 4188_CR10
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/not112
SSID ssj0004731
Score 2.423498
SecondaryResourceType review_article
Snippet Purpose 5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant...
5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant gliomas....
Purpose5-aminolevulinic acid (5-ALA) has demonstrated its utility as an intraoperative imaging adjunct during fluorescence guided resection of malignant...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 669
SubjectTerms Aminolevulinic Acid
Brain cancer
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - pathology
Brain Neoplasms - surgery
Brain tumors
Fluorescence
Glioma
Glioma - pathology
Humans
Medicine
Medicine & Public Health
Metastases
Metastasis
Neuroimaging
Neurology
Neuronavigation - methods
Oncology
Retrospective Studies
Review
Surgery, Computer-Assisted - methods
Survival
Systematic review
Tumors
SummonAdditionalLinks – databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fS8MwEA4yQXwRf1udEsE3DaRJmjS-DXEMcT45GPhQ0iYVYa6ydQ_-9166dkWmgs-9puUuyX3H3XeH0JUVAKqtFkQYlhGhYk4MY46EEDArmaeaxZ6NPHySg5F4GEfjmhQ2b6rdm5RkdVO3ZDeIXijx1edUhGBfCNQ3I99PCnbxiPVaNqSqpxDCFRBpMa6pMj-v8d0drWHMtfxo5Xb6u2inxou4tzTwHtpw0320Nawz4gfoZVT66tZPXOQ4Ir3HHgYUivPJophVjZoyR14Xb9ZZ7HlGFYnBi6Z-MgR-d6UBdDh381tscNvUGS8JLYdo1L9_vhuQemACybiKSuLA3VCT6YhlKrbC8DjzFB1pLeAsYwCcUa7zOOTWGsrzUEoVuihPAbLxTCrOj1BnWkzdCcKhUMKylMsUfHyaS21jn1HVihqnDXUBChu9JVndTdwPtZgkbR9kr-sEdJ1Uuk5ogK5X73wse2n8Kd1tzJHU52qeMAURlc8GsgBdrh7DifBpDjN1xcLL8CgGmMpkgI6XZlx9jkuuKNMiQDeNXdvFf_-X0_-Jn6Ft5vdYVfXSRZ1ytnDngF3K9KLaql9MsuBC
  priority: 102
  providerName: Springer Nature
Title Utility of 5-ALA for fluorescence-guided resection of brain metastases: a systematic review
URI https://link.springer.com/article/10.1007/s11060-022-04188-0
https://www.ncbi.nlm.nih.gov/pubmed/36370294
https://www.proquest.com/docview/2755001222
https://www.proquest.com/docview/2735865626
Volume 160
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fi9QwEB68OxBfxN9XPZcIvmkwTdKk9UW6x66HeouICys-lDRJRTi35233wf_eTJvdIof31IekbZiZJF8y880AvHQygGpXSCoNt1TqXFDDuadpODBr1dQFz5GNfL5QZ0v5YZWt4oXbJoZV7tbEfqF2rcU78jdcByyNfiD-7vI3xapR6F2NJTQO4Ag5oHj4yk_HEA-pYz3CsBhkhVxF0sxAnQtnIUYxlp3JNFgL-3djuoY2r3lK-w1ofg_uRuRIykHV9-GWXz-A2-fRN_4Qvi87jHP9Q9qGZLT8VJKAR0lzsW2v-pRN1tMf25_OO4KMo57OgF1rrBFBfvnOBJy48Zu3xJAxvTMZqC2PYDmffT09o7F0ArVCZx31YeNhxhYZtzp30ojcIllHORcQlzEBpjFRNHkqnDNMNKlSOvVZUwfwJqzSQjyGw3W79sdAUqml47VQddjt60YVLkffaqGZ8YVhPoF0J7fKxrziWN7iohozIqOsqyDrqpd1xRJ4tX_ncsiqcWPvk506qjjDNtVoDwm82DeHuYEOD7P27Rb7iCwPgJWrBJ4Matz_TiihGS9kAq93eh0__v-xPL15LM_gDkeb6uNdTuCwu9r65wG1dPUEDvRKT3oDncBROZ9OF_h8_-3jLDyns8XnL6F1ycu_Cc3piw
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwED5NnQS8IH4TGGAkeAILx3bsBGlCBTZ1rK0QWqVKPAQndtCkrRlrKrR_jr8NX-K0QhN723Oc2Lo7n7_47rsDeGWlB9U2k1QaXlKpU0EN547G_odZq6rIeIps5MlUjWbyyzyZb8GfnguDaZW9T2wdta1LvCN_x7XH0hgH4h_OflHsGoXR1b6FhgmtFexuW2IsEDsO3cVv_wu33D347PX9mvP9vaNPIxq6DNBS6KShzvtoZsos4aVOrTQiLZHXoqz14MQYj2iYyKo0FtYaJqpYKR27pCo8zhGl0ngh6o-AbYkXKAPY_rg3_fptw8zUoSOid0dJJueBttOR9_wkjGI2PZOxt1f279F4Ce9eitW2R-D-HbgdsCsZdsZ2F7bc4h7cmITo_H34Pmsw0_aC1BVJ6HA8JB4Rk-pkVZ-3RaNKR3-ujq2zBDlPLaEChxbYpYKcusZ4pLp0y_fEkE2BadKRax7A7FrE-hAGi3rhHgOJpZaWF0IVHm8UlcpsitHdTDPjMsNcBHEvt7wMlc2xwcZJvqnJjLLOvazzVtY5i-DN-p2zrq7HlaN3enXkYY8v841FRvBy_djvTgy5mIWrVzhGJKmHzFxF8KhT43o6oYRmPJMRvO31uvn4_9fy5Oq1vICbo6PJOB8fTA-fwi2O9tVm3-zAoDlfuWceQzXF82CoBH5c9974Cz_1JP0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fa9RAEB5KC8UX8bfRqivoky7d7G52E6HIaXu0tj2KeHDgQ9xkN1JoL7WXQ_ov-lc5m2wuSLFvfc4mu8zOznybmW8G4I2VCKptJqk0vKRSp4Iazh2N8cKsVVVkPPVs5OOJ2p_KL7NktgZ_ei6MT6vsbWJrqG1d-n_k21wjlvZxIL5dhbSIk93xx4tf1HeQ8pHWvp2GCW0W7E5bbiyQPA7d1W-8zi12DnZx799yPt779nmfho4DtBQ6aahDe81MmSW81KmVRqSl57goaxGoGIPohomsSmNhrWGiipXSsUuqAjGPKJX2P0fRHWxo9Pp4Edz4tDc5-TqwNHXojoimKcnkLFB4OiIfTsKoz6xnMkbdZf-6yWvY91rctnWH43twN-BYMuoU7z6sufkD2DwOkfqH8H3a-KzbK1JXJKGjoxFBdEyqs2V92RaQKh39uTy1zhLPf2rJFX5o4TtWkHPXGEStC7f4QAwZik2TjmjzCKa3ItbHsD6v5-4pkFhqaXkhVIHYo6hUZlMf6c00My4zzEUQ93LLy1Dl3DfbOMuH-sxe1jnKOm9lnbMI3q3euehqfNw4eqvfjjyc90U-aGcEr1eP8aT68IuZu3rpx4gkRfjMVQRPum1cTSeU0IxnMoL3_b4OH___Wp7dvJZXsIlnJD86mBw-hzvcq1ebiLMF683l0r1AONUUL4OeEvhx20fjL2zmKUE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Utility+of+5-ALA+for+fluorescence-guided+resection+of+brain+metastases%3A+a+systematic+review&rft.jtitle=Journal+of+neuro-oncology&rft.au=Shah%2C+Harshal+A&rft.au=Leskinen%2C+Sandra&rft.au=Khilji%2C+Hamza&rft.au=Narayan%2C+Vinayak&rft.date=2022-12-01&rft.eissn=1573-7373&rft.volume=160&rft.issue=3&rft.spage=669&rft_id=info:doi/10.1007%2Fs11060-022-04188-0&rft_id=info%3Apmid%2F36370294&rft.externalDocID=36370294
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-594X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-594X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-594X&client=summon